These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 19540293)
21. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies. Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785 [TBL] [Abstract][Full Text] [Related]
22. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model. Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194 [TBL] [Abstract][Full Text] [Related]
23. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. Krovat EM; Frühwirth KH; Langer T J Chem Inf Model; 2005; 45(1):146-59. PubMed ID: 15667140 [TBL] [Abstract][Full Text] [Related]
24. Synthesis of 3'-ureidoadenosine analogues and their binding affinity to the A3 adenosine receptor. Chun MW; Lee HW; Kim AY; Kim MJ; Kim HO; Gao ZG; Jacobson KA; Jeong LS Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):1119-21. PubMed ID: 16248104 [TBL] [Abstract][Full Text] [Related]
25. Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies. Colotta V; Capelli F; Lenzi O; Catarzi D; Varano F; Poli D; Vincenzi F; Varani K; Borea PA; Dal Ben D; Volpini R; Cristalli G; Filacchioni G Bioorg Med Chem; 2009 Jan; 17(1):401-10. PubMed ID: 18996701 [TBL] [Abstract][Full Text] [Related]
26. Molecular modeling of the second extracellular loop of G-protein coupled receptors and its implication on structure-based virtual screening. de Graaf C; Foata N; Engkvist O; Rognan D Proteins; 2008 May; 71(2):599-620. PubMed ID: 17972285 [TBL] [Abstract][Full Text] [Related]
27. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Yu H; Wang Z; Zhang L; Zhang J; Huang Q Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906 [TBL] [Abstract][Full Text] [Related]
28. Deciphering ligand dependent degree of binding site closure and its implication in inhibitor design: A modeling study on human adenosine kinase. Bhutoria S; Ghoshal N J Mol Graph Model; 2010 Feb; 28(6):577-91. PubMed ID: 20089430 [TBL] [Abstract][Full Text] [Related]
29. 3D-pharmacophore models for selective A2A and A2B adenosine receptor antagonists. Wei J; Wang S; Gao S; Dai X; Gao Q J Chem Inf Model; 2007; 47(2):613-25. PubMed ID: 17330954 [TBL] [Abstract][Full Text] [Related]
30. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. López-Rodríguez ML; Benhamú B; de la Fuente T; Sanz A; Pardo L; Campillo M J Med Chem; 2005 Jun; 48(13):4216-9. PubMed ID: 15974573 [TBL] [Abstract][Full Text] [Related]
31. QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors. Borghini A; Pietra D; Domenichelli P; Bianucci AM Bioorg Med Chem; 2005 Sep; 13(18):5330-7. PubMed ID: 15990318 [TBL] [Abstract][Full Text] [Related]
33. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models. Ravikumar M; Pavan S; Bairy S; Pramod AB; Sumakanth M; Kishore M; Sumithra T Chem Biol Drug Des; 2008 Jul; 72(1):79-90. PubMed ID: 18498326 [TBL] [Abstract][Full Text] [Related]
34. Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein. Steindl TM; Crump CE; Hayden FG; Langer T J Med Chem; 2005 Oct; 48(20):6250-60. PubMed ID: 16190752 [TBL] [Abstract][Full Text] [Related]
35. Discovery of potential integrin VLA-4 antagonists using pharmacophore modeling, virtual screening and molecular docking studies. Thangapandian S; John S; Sakkiah S; Lee KW Chem Biol Drug Des; 2011 Aug; 78(2):289-300. PubMed ID: 21507205 [TBL] [Abstract][Full Text] [Related]
36. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor. Kahnberg P; Howard MH; Liljefors T; Nielsen M; Nielsen EØ; Sterner O; Pettersson I J Mol Graph Model; 2004 Dec; 23(3):253-61. PubMed ID: 15530821 [TBL] [Abstract][Full Text] [Related]
37. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies. Yuzlenko O; Kieć-Kononowicz K J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794 [TBL] [Abstract][Full Text] [Related]
38. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Wolber G; Langer T J Chem Inf Model; 2005; 45(1):160-9. PubMed ID: 15667141 [TBL] [Abstract][Full Text] [Related]